On 23 and 24 July 2025, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) convened to review seven peptide-related compounds being considered for potential inclusion on the 503A Bulks List. After two days of discussion, six of the seven received positive recommendations from the committee. One did not. For a field that has operated in a